Ceribell, Inc. Income Statement
CBLL / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Ceribell, Inc. reported $89M in revenue and $53M in net loss for FY2025. Revenue has grown at a 40.3% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $89.1M | $45.2M | $45.2M |
| Cost of Revenue | $10.8M | $7.1M | $7.1M |
| Gross Profit | $78.3M | $38.2M | $38.2M |
| SG&A Expense | $44.5M | $20.3M | $20.3M |
| R&D Expense | $19.1M | $9.0M | $9.0M |
| Operating Income | -$58.4M | -$30.0M | -$30.0M |
| Income Tax | $0 | $11.0K | $11.0K |
| Net Income | -$53.4M | -$29.5M | -$29.5M |
| EPS (Basic) | -$1.46 | -$5.56 | -$5.56 |
| EPS (Diluted) | -$1.46 | -$5.56 | -$5.56 |
| Shares Outstanding | 37.5M | 5.4M | 5.3M |
| Gross Margin | 87.9% | 84.4% | 84.4% |
| Operating Margin | -65.6% | -66.4% | -66.4% |
| Profit Margin | -60.0% | -65.1% | -65.1% |